Categories: AddictionBrainNews

Ibogaine by David Dardashti Introduces New Algorithm for Methadone Addiction

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Algorithm Varies Slightly from Suboxone and Focuses on Continuously Dosed Ibogaine Treatment

Methadone algorithm

Ibogaine by David Dardashti is improving treatment through biotechnologyIbogaine by David Dardashti is improving treatment through biotechnology
Ibogaine by David Dardashti is improving treatment through biotechnology

MIAMI, April 21, 2024 (GLOBE NEWSWIRE) — The novel algorithm signifies a notable deviation from Suboxone, a frequently administered medication for treating opioid addiction, as it incorporates synthetic methadone. Methadone, a man-made opioid, functions by attaching to the same brain receptors as other opioids, but it has a slower onset and longer-lasting effects. This characteristic enables it to mitigate cravings and withdrawal symptoms without eliciting the same strong euphoria as other opioids.

By integrating methadone into the algorithm, medical practitioners can propose an alternative method for patients to manage their addiction, potentially enhancing results for those grappling with opioid use disorder. Upon reaching the clinic, patients will be given preliminary doses of ibogaine to ready their bodies for the main treatment doses. These preliminary doses aim to increase the patient’s tolerance and ensure they are prepared for the complete treatment. Furthermore, patients will also receive preliminary doses two days before leaving the clinic. This is intended to sustain the treatment’s effects and offer ongoing support as they reintegrate into their everyday lives.

The primary doses of ibogaine treatment will be uniformly distributed between the initial and final booster doses. This method allows for a steady and regulated dispensation of the drug, guaranteeing that the patient fully benefits from the therapy. By distributing the doses in this manner, the clinic can track the patient’s progress and modify the treatment plan as necessary to secure the best possible results. In essence, this ibogaine dosing strategy aims to optimize the treatment’s efficacy and aid the patient’s path to healing and recovery.

David Dardashti, the founder of Ibogaine by David Dardashti, remarks, “We’re thrilled to launch this new treatment regimen. We are confident that the application of ibogaine, coupled with a sustained dosage strategy, will assist those battling methadone addiction to transform their lives.” The base doses, which will be dispensed following a thorough assessment of the patient, will be administered in equal quantities daily to promote consistent treatment progress. The staff at Ibogaine by David Dardashti will be on hand throughout the entire procedure to ensure the patient’s safety and comfort.

David Dardashti
+17869301880
gavriel@ibogaineclinic.com

A photo accompanying this announcement is available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/ab7ae429-452b-477c-85d0-8449f6dfeda0

Staff

Recent Posts

SI Group Awarded Bronze Medal by EcoVadis for Corporate Social Responsibility

Company Ranked in the Top 35% of All Rated Companies Underscoring the Company's Commitment to…

5 hours ago

S-E-A Expands Forensic Capabilities with High-Tech Industrial CT Scanner

COLUMBUS, Ohio, March 19, 2025 /PRNewswire/ -- Computed Tomography (CT) scanning, once primarily associated with medical…

5 hours ago

Tech Mahindra and NVIDIA Collaborate to Advance Drug Safety with Agentic AI-Powered Pharmacovigilance Solution

PUNE, India, March 19, 2025 /PRNewswire/ -- Tech Mahindra (NSE: TECHM), a leading global provider…

5 hours ago

Stanford Medicine and LEADOPTIK Announce Research Collaboration to Advance AI-Enhanced, Real-Time Optical Imaging in Lung Cancer Biopsy

SAN JOSE, Calif., March 19, 2025 /PRNewswire/ -- LEADOPTIK Inc., a Silicon Valley-based medical imaging…

5 hours ago

NASDAQ-listed TNL Mediagene Provides AI-Powered CMS Technology to Japanese Publishers

NEW YORK and TOKYO, March 19, 2025 /PRNewswire/ -- Mediagene Inc., a group company of…

5 hours ago

Sisram Medical Announces 2024 Annual Results

New product launches drive double-digit growth in key markets and deliver market outperformance amid economic…

5 hours ago